Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

159 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Improvement in the survival of patients with stage IV non-small-cell lung cancer: Experience in a single institutional 1995-2017.
Takano N, Ariyasu R, Koyama J, Sonoda T, Saiki M, Kawashima Y, Oguri T, Hisakane K, Uchibori K, Nishikawa S, Kitazono S, Yanagitani N, Ohyanagi F, Horiike A, Gemma A, Nishio M. Takano N, et al. Among authors: yanagitani n. Lung Cancer. 2019 May;131:69-77. doi: 10.1016/j.lungcan.2019.03.008. Epub 2019 Mar 21. Lung Cancer. 2019. PMID: 31027701
Correlation between thyroid transcription factor-1 expression, immune-related thyroid dysfunction, and efficacy of anti-programmed cell death protein-1 treatment in non-small cell lung cancer.
Koyama J, Horiike A, Yoshizawa T, Dotsu Y, Ariyasu R, Saiki M, Sonoda T, Uchibori K, Nishikawa S, Kitazono S, Yanagitani N, Ninomiya H, Ishikawa Y, Nishio M. Koyama J, et al. Among authors: yanagitani n. J Thorac Dis. 2019 May;11(5):1919-1928. doi: 10.21037/jtd.2019.04.102. J Thorac Dis. 2019. PMID: 31285885 Free PMC article.
Barcode sequencing identifies resistant mechanisms to epidermal growth factor receptor inhibitors in circulating tumor DNA of lung cancer patients.
Kitazono S, Sakai K, Yanagitani N, Ariyasu R, Yoshizawa T, Dotsu Y, Koyama J, Saiki M, Sonoda T, Nishikawa S, Uchibori K, Horiike A, Nishio K, Nishio M. Kitazono S, et al. Among authors: yanagitani n. Cancer Sci. 2019 Oct;110(10):3350-3357. doi: 10.1111/cas.14153. Epub 2019 Aug 19. Cancer Sci. 2019. PMID: 31361375 Free PMC article.
Association of High Neutrophil-to-Lymphocyte Ratio With Poor Outcomes of Pembrolizumab Therapy in High-PD-L1-expressing Non-small Cell Lung Cancer.
Hasegawa T, Yanagitani N, Utsumi H, Wakui H, Sakamoto H, Tozuka T, Yoshida H, Amino Y, Uematsu S, Yoshizawa T, Uchibori K, Kitazono S, Horiike A, Horai T, Kuwano K, Nishio M. Hasegawa T, et al. Among authors: yanagitani n. Anticancer Res. 2019 Dec;39(12):6851-6857. doi: 10.21873/anticanres.13902. Anticancer Res. 2019. PMID: 31810952
Dissociated responses at initial computed tomography evaluation is a good prognostic factor in non-small cell lung cancer patients treated with anti-programmed cell death-1/ligand 1 inhibitors.
Tozuka T, Kitazono S, Sakamoto H, Yoshida H, Amino Y, Uematsu S, Yoshizawa T, Hasegawa T, Uchibori K, Yanagitani N, Horiike A, Horai T, Seike M, Gemma A, Nishio M. Tozuka T, et al. Among authors: yanagitani n. BMC Cancer. 2020 Mar 12;20(1):207. doi: 10.1186/s12885-020-6704-z. BMC Cancer. 2020. PMID: 32164651 Free PMC article.
Poor efficacy of anti-programmed cell death-1/ligand 1 monotherapy for non-small cell lung cancer patients with active brain metastases.
Tozuka T, Kitazono S, Sakamoto H, Yoshida H, Amino Y, Uematsu S, Yoshizawa T, Hasegawa T, Ariyasu R, Uchibori K, Yanagitani N, Horai T, Seike M, Gemma A, Nishio M. Tozuka T, et al. Among authors: yanagitani n. Thorac Cancer. 2020 Sep;11(9):2465-2472. doi: 10.1111/1759-7714.13557. Epub 2020 Jul 12. Thorac Cancer. 2020. PMID: 32657011 Free PMC article.
159 results